292 related articles for article (PubMed ID: 21908615)
1. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
[TBL] [Abstract][Full Text] [Related]
2. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
3. Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.
Hatton O; Lambert SL; Krams SM; Martinez OM
PLoS One; 2012; 7(8):e42610. PubMed ID: 22880054
[TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr virus causes epithelial-mesenchymal transition in human corneal epithelial cells via Syk/src and Akt/Erk signaling pathways.
Park GB; Kim D; Kim YS; Kim S; Lee HK; Yang JW; Hur DY
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1770-9. PubMed ID: 24569586
[TBL] [Abstract][Full Text] [Related]
5. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.
Incrocci R; Barse L; Stone A; Vagvala S; Montesano M; Subramaniam V; Swanson-Mungerson M
Virology; 2017 Jan; 500():96-102. PubMed ID: 27792904
[TBL] [Abstract][Full Text] [Related]
7. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αv-integrin membrane translocation.
Fotheringham JA; Coalson NE; Raab-Traub N
J Virol; 2012 Oct; 86(19):10308-20. PubMed ID: 22837212
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.
Hatton O; Martinez OM; Esquivel CO
Pediatr Transplant; 2012 May; 16(3):220-9. PubMed ID: 22353174
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
Cooper L; Longnecker R
Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract][Full Text] [Related]
14. SYK regulates mTOR signaling in AML.
Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
[TBL] [Abstract][Full Text] [Related]
15. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
16. EBV-encoded miRNAs BHRF1-1 and BART2-5p aggravate post- transplant lymphoproliferative disorder via LZTS2-PI3K-AKT axis.
Ji H; Yang T; Li C; Zhu Y; Zheng Z; Zhang J; Liu Y; Gao Y; Wu H; Jiang J; Yong J; Chen M; Tang Y; Xia Q; Xue F
Biochem Pharmacol; 2023 Aug; 214():115676. PubMed ID: 37419372
[TBL] [Abstract][Full Text] [Related]
17. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
18. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
19. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.
Swart R; Ruf IK; Sample J; Longnecker R
J Virol; 2000 Nov; 74(22):10838-45. PubMed ID: 11044134
[TBL] [Abstract][Full Text] [Related]
20. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
